Costs of influenza in germany 1996 - A cost-of-illness study;Volkswirtschaftliche kosten der influenza 1996 eine krankheitskostenstudie

Medizinische Klinik

Volumn 96, Issue 2, 2001, Pages 63-70

  Szucs, Thomas ^a   Behrens, Monika ^b   Volmer, Timm ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Glaxo Wellcome   (Germany)

Author keywords

Costs; Epidemic; Health economics; Influenza; Neuraminidase inhibitor; Zanamivir

Indexed keywords

ARTICLE; GERMANY; HEALTH CARE COST; HUMAN; INFLUENZA; SOCIOECONOMICS;

EID: 0035865178     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00002180     Document Type: Article

References (24)

1. Influenza vaccination in 29 countries: An update to 1997
2. What are the complications of influenza and can they be prevented? Experience from the 1989 epidemic of H3N2 influenza A in gereral practice
3. Decreasing antibiotic use in ambulatory practice: Impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults
4. Ökonomische bedeutung der schutzimpfung
5. Indirect costs in economic studies
6. Influenza 1995/96-Ergebnisse zweier deutscher Überwachungssysteme
7. Influenzaimpfung
8. Influence of patient's expectations on antibiotic management of acute lower respiratory tract illness in general practice: Questionnaire study
9. The efficacy and safety of zanamivit in the treatment of influenza in otherwise healthy and high risk adults
10. Impact of influenza on mortality in relation to age and underlying disease. 1967-1989
11. Influenza: Just a medical challenge? Abstract book: Meeting the challenge of influenza
12. The role of burden-of-illness research
13. New approaches to influenza vaccines: High doses, neuraminidase vaccines, alternative substrates, and new adjuvants